Skip to main content

John Sargent Sundy

Adjunct Professor in the Department of Medicine
Medicine, Rheumatology and Immunology
Duke Box 3278, 3854 Clinic 3N, Duke Clinic, Durham, NC 27710
Gilead Sciences, 333 Lakeside Dr, Foster City, CA 94404

Selected Publications


Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).

Journal Article Mod Rheumatol · February 28, 2022 OBJECTIVES: Evaluate the efficacy and safety of the Janus kinase-1 inhibitor filgotinib in Japanese patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX). METHODS: Data from 147 Japanese patients in FINCH 1, a 52-week global ... Full text Link to item Cite

Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).

Journal Article Mod Rheumatol · February 28, 2022 OBJECTIVES: To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure. METHODS: Data up to 24 weeks were analysed for 71 Japanese patients from a 52-week globa ... Full text Link to item Cite

Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).

Journal Article Mod Rheumatol · January 5, 2022 OBJECTIVES: To evaluate efficacy and safety of filgotinib in Japanese RA patients who have failed or were intolerant to one or more biologic disease-modifying antirheumatic drugs (bDMARD) from the global FINCH 2 study (NCT02873936). METHODS: This subgroup ... Full text Link to item Cite

Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.

Journal Article J Rheumatol · August 2021 OBJECTIVE: The long-term safety and efficacy of filgotinib (from phase II studies), with or without methotrexate (MTX), for the treatment of patients with rheumatoid arthritis was assessed in DARWIN 3, a long-term, open-label extension study (ClinicalTrial ... Full text Link to item Cite

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.

Journal Article Ann Rheum Dis · July 2021 OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexat ... Full text Link to item Cite

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.

Journal Article Ann Rheum Dis · June 2021 OBJECTIVES: To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure. METHODS: This 52-week, phase 3, multicentre, double-blind clin ... Full text Link to item Cite

Risk factors for disease progression in idiopathic pulmonary fibrosis.

Journal Article Thorax · January 2020 In this retrospective study of a randomised trial of simtuzumab in idiopathic pulmonary fibrosis (IPF), prodromal decline in forced vital capacity (FVC) was significantly associated with increased risk of mortality, respiratory and all-cause hospitalisatio ... Full text Link to item Cite

Effects of Selonsertib in Patients with Diabetic Kidney Disease.

Journal Article J Am Soc Nephrol · October 2019 BACKGROUND: Apoptosis signal-regulating kinase 1 (ASK1) activation in glomerular and tubular cells resulting from oxidative stress may drive kidney disease progression. Findings in animal models identified selonsertib, a selective ASK1 inhibitor, as a pote ... Full text Link to item Cite

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Journal Article JAMA · July 23, 2019 IMPORTANCE: Patients with active rheumatoid arthritis (RA) despite treatment with biologic disease-modifying antirheumatic drug (bDMARD) therapy need treatment options. OBJECTIVE: To evaluate the effects of filgotinib vs placebo on the signs and symptoms o ... Full text Link to item Cite

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Journal Article Am J Respir Crit Care Med · July 15, 2019 Rationale: Several common and rare genetic variants have been associated with idiopathic pulmonary fibrosis, a progressive fibrotic condition that is localized to the lung. Objectives: To develop an integrated understanding of the rare and common variants ... Full text Link to item Cite

SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Journal Article JCI Insight · October 4, 2018 Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletinib (EN ... Full text Link to item Cite

Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.

Journal Article Eur Respir J · September 2018 We evaluated performance characteristics and estimated the minimal clinically important difference (MCID) of data-driven texture analysis (DTA), a high-resolution computed tomography (HRCT)-derived measurement of lung fibrosis, in subjects with idiopathic ... Full text Link to item Cite

Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.

Journal Article J Crohns Colitis · August 29, 2018 BACKGROUND AND AIMS: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of ulcerative colitis [UC] via disruption of intestinal barrier integrity and function. A phase 2/3 combined trial was designed to examine the efficacy, safety, and ph ... Full text Link to item Cite

A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease.

Journal Article J Crohns Colitis · August 29, 2018 BACKGROUND AND AIMS: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of Crohn's disease and may serve as a potential biomarker. A phase 2 trial was conducted to examine the efficacy and safety of the anti-MMP9 antibody andecaliximab [GS ... Full text Link to item Cite

Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.

Journal Article Thorax · January 2018 BACKGROUND: Assessing functional impairment, therapeutic response and disease progression in patients with idiopathic pulmonary fibrosis (IPF) continues to be challenging. Hyperpolarized 129Xe MRI can address this gap through its unique capability to image ... Full text Link to item Cite

Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis.

Journal Article Clin Ther · January 2018 PURPOSE: Andecaliximab (GS-5745) is a highly selective monoclonal antibody against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the pathogenesis of rheumatoid arthritis (RA). This study assessed the safety and pharmacokinetic (PK) ... Full text Link to item Cite

The cortisol:C-reactive protein ratio and negative affect reactivity in depressed adults.

Journal Article Health Psychol · September 2017 OBJECTIVE: We evaluated the effect of the cortisol (CORT) to high sensitivity C-reactive protein (hsCRP) ratio on stress-induced negative affect (NA) reactivity and whether the association was moderated by depressive symptom severity and gender. The CORT/C ... Full text Link to item Cite

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.

Journal Article Ann Rheum Dis · June 2016 OBJECTIVES: To assess the efficacy and tolerability of lesinurad, an oral selective uric acid reabsorption inhibitor, in combination with allopurinol versus allopurinol alone in patients with gout and an inadequate response to allopurinol. METHODS: Patient ... Full text Link to item Cite

2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Journal Article Arthritis Rheumatol · October 2015 OBJECTIVE: Existing criteria for the classification of gout have suboptimal sensitivity and/or specificity, and were developed at a time when advanced imaging was not available. The current effort was undertaken to develop new classification criteria for g ... Full text Link to item Cite

Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).

Journal Article Mod Rheumatol · February 28, 2022 OBJECTIVES: Evaluate the efficacy and safety of the Janus kinase-1 inhibitor filgotinib in Japanese patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX). METHODS: Data from 147 Japanese patients in FINCH 1, a 52-week global ... Full text Link to item Cite

Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).

Journal Article Mod Rheumatol · February 28, 2022 OBJECTIVES: To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure. METHODS: Data up to 24 weeks were analysed for 71 Japanese patients from a 52-week globa ... Full text Link to item Cite

Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).

Journal Article Mod Rheumatol · January 5, 2022 OBJECTIVES: To evaluate efficacy and safety of filgotinib in Japanese RA patients who have failed or were intolerant to one or more biologic disease-modifying antirheumatic drugs (bDMARD) from the global FINCH 2 study (NCT02873936). METHODS: This subgroup ... Full text Link to item Cite

Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.

Journal Article J Rheumatol · August 2021 OBJECTIVE: The long-term safety and efficacy of filgotinib (from phase II studies), with or without methotrexate (MTX), for the treatment of patients with rheumatoid arthritis was assessed in DARWIN 3, a long-term, open-label extension study (ClinicalTrial ... Full text Link to item Cite

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.

Journal Article Ann Rheum Dis · July 2021 OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexat ... Full text Link to item Cite

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.

Journal Article Ann Rheum Dis · June 2021 OBJECTIVES: To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure. METHODS: This 52-week, phase 3, multicentre, double-blind clin ... Full text Link to item Cite

Risk factors for disease progression in idiopathic pulmonary fibrosis.

Journal Article Thorax · January 2020 In this retrospective study of a randomised trial of simtuzumab in idiopathic pulmonary fibrosis (IPF), prodromal decline in forced vital capacity (FVC) was significantly associated with increased risk of mortality, respiratory and all-cause hospitalisatio ... Full text Link to item Cite

Effects of Selonsertib in Patients with Diabetic Kidney Disease.

Journal Article J Am Soc Nephrol · October 2019 BACKGROUND: Apoptosis signal-regulating kinase 1 (ASK1) activation in glomerular and tubular cells resulting from oxidative stress may drive kidney disease progression. Findings in animal models identified selonsertib, a selective ASK1 inhibitor, as a pote ... Full text Link to item Cite

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Journal Article JAMA · July 23, 2019 IMPORTANCE: Patients with active rheumatoid arthritis (RA) despite treatment with biologic disease-modifying antirheumatic drug (bDMARD) therapy need treatment options. OBJECTIVE: To evaluate the effects of filgotinib vs placebo on the signs and symptoms o ... Full text Link to item Cite

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Journal Article Am J Respir Crit Care Med · July 15, 2019 Rationale: Several common and rare genetic variants have been associated with idiopathic pulmonary fibrosis, a progressive fibrotic condition that is localized to the lung. Objectives: To develop an integrated understanding of the rare and common variants ... Full text Link to item Cite

SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Journal Article JCI Insight · October 4, 2018 Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletinib (EN ... Full text Link to item Cite

Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.

Journal Article Eur Respir J · September 2018 We evaluated performance characteristics and estimated the minimal clinically important difference (MCID) of data-driven texture analysis (DTA), a high-resolution computed tomography (HRCT)-derived measurement of lung fibrosis, in subjects with idiopathic ... Full text Link to item Cite

Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.

Journal Article J Crohns Colitis · August 29, 2018 BACKGROUND AND AIMS: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of ulcerative colitis [UC] via disruption of intestinal barrier integrity and function. A phase 2/3 combined trial was designed to examine the efficacy, safety, and ph ... Full text Link to item Cite

A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease.

Journal Article J Crohns Colitis · August 29, 2018 BACKGROUND AND AIMS: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of Crohn's disease and may serve as a potential biomarker. A phase 2 trial was conducted to examine the efficacy and safety of the anti-MMP9 antibody andecaliximab [GS ... Full text Link to item Cite

Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.

Journal Article Thorax · January 2018 BACKGROUND: Assessing functional impairment, therapeutic response and disease progression in patients with idiopathic pulmonary fibrosis (IPF) continues to be challenging. Hyperpolarized 129Xe MRI can address this gap through its unique capability to image ... Full text Link to item Cite

Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis.

Journal Article Clin Ther · January 2018 PURPOSE: Andecaliximab (GS-5745) is a highly selective monoclonal antibody against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the pathogenesis of rheumatoid arthritis (RA). This study assessed the safety and pharmacokinetic (PK) ... Full text Link to item Cite

The cortisol:C-reactive protein ratio and negative affect reactivity in depressed adults.

Journal Article Health Psychol · September 2017 OBJECTIVE: We evaluated the effect of the cortisol (CORT) to high sensitivity C-reactive protein (hsCRP) ratio on stress-induced negative affect (NA) reactivity and whether the association was moderated by depressive symptom severity and gender. The CORT/C ... Full text Link to item Cite

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.

Journal Article Ann Rheum Dis · June 2016 OBJECTIVES: To assess the efficacy and tolerability of lesinurad, an oral selective uric acid reabsorption inhibitor, in combination with allopurinol versus allopurinol alone in patients with gout and an inadequate response to allopurinol. METHODS: Patient ... Full text Link to item Cite

2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Journal Article Arthritis Rheumatol · October 2015 OBJECTIVE: Existing criteria for the classification of gout have suboptimal sensitivity and/or specificity, and were developed at a time when advanced imaging was not available. The current effort was undertaken to develop new classification criteria for g ... Full text Link to item Cite

2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Journal Article Ann Rheum Dis · October 2015 OBJECTIVE: Existing criteria for the classification of gout have suboptimal sensitivity and/or specificity, and were developed at a time when advanced imaging was not available. The current effort was undertaken to develop new classification criteria for g ... Full text Link to item Cite

The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.

Journal Article Chest · October 2015 BACKGROUND: The National Heart, Lung, and Blood Institute-sponsored IPF Clinical Research Network (IPFnet) studies enrolled subjects with idiopathic pulmonary fibrosis (IPF) to evaluate drug therapies in treatment trials. An adjudication committee (AC) pro ... Full text Link to item Cite

Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial.

Journal Article JAMA · May 26, 2015 IMPORTANCE: Soy isoflavone supplements are used to treat several chronic diseases, although the data supporting their use are limited. Some data suggest that supplementation with soy isoflavone may be an effective treatment for patients with poor asthma co ... Full text Link to item Cite

Depressogenic vulnerability and gender-specific patterns of neuro-immune dysregulation: What the ratio of cortisol to C-reactive protein can tell us about loss of normal regulatory control.

Journal Article Brain Behav Immun · February 2015 We examined whether the ratio of cortisol (CORT) to high-sensitivity C-reactive protein (hsCRP), an index that captures the integrity of homeostatic regulation between the hypothalamic-pituitary-adrenal (HPA) axis and inflammatory processes, is associated ... Full text Link to item Cite

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.

Journal Article J Clin Rheumatol · December 2014 BACKGROUND: In clinical trials of pegloticase, a PEGylated uricase developed for treatment of gout refractory to conventional therapy, infusion-related reactions (IRs) were the second most frequent adverse event reported. OBJECTIVE: The objective of this s ... Full text Link to item Cite

Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.

Journal Article J Rheumatol · August 2014 OBJECTIVE: To evaluate the safety and efficacy of once-weekly subcutaneous rilonacept 160 mg for prevention of gout flares in patients initiating or continuing urate-lowering therapy (ULT). METHODS: This phase III study was conducted in the United States, ... Full text Link to item Cite

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.

Journal Article Arthritis Res Ther · March 7, 2014 INTRODUCTION: Pegloticase, a PEGylated recombinant porcine uricase, is approved for treating refractory gout at a dose of 8 mg intravenous (IV) every 2 weeks. However, during phase 1 testing, pharmacokinetics supported less frequent dosing. Also, single do ... Full text Link to item Cite

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

Journal Article Arthritis Research and Therapy · March 7, 2014 Introduction: Pegloticase, a PEGylated recombinant porcine uricase, is approved for treating refractory gout at a dose of 8 mg intravenous (IV) every 2 weeks. However, during phase 1 testing, pharmacokinetics supported less frequent dosing. Also, single do ... Full text Cite

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

Journal Article Arthritis Res Ther · March 4, 2014 INTRODUCTION: The efficacy of pegloticase, a polyethylene glycol (PEG)-conjugated mammalian recombinant uricase, approved for chronic refractory gout, can be limited by the development of antibodies (Ab). Analyses from 2 replicate, 6-month, randomized cont ... Full text Link to item Cite

OMERACT endorsement of measures of outcome for studies of acute gout.

Journal Article J Rheumatol · March 2014 OBJECTIVE: To determine the extent to which participants at the Outcome Measures in Rheumatology (OMERACT) 11 meeting agree that instruments used in clinical trials to measure OMERACT core outcome domains in acute gout fulfill OMERACT filter requirements o ... Full text Link to item Cite

Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.

Journal Article Arthritis Care Res (Hoboken) · January 2014 OBJECTIVE: Tophi are strongly associated with structural damage in gout, and urate-lowering therapy reduces tophus size. Pegloticase leads to dramatic reductions in serum urate and subcutaneous tophi in treatment responders. The aim of this analysis was to ... Full text Link to item Cite

Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.

Journal Article Respir Med · January 2014 BACKGROUND: Dyspnea is a hallmark symptom of idiopathic pulmonary fibrosis (IPF), and dyspnea induced physical activity limitation is a prominent driver of quality of life impairment among IPF patients. METHODS: We examined response data for the 21 physica ... Full text Link to item Cite

Using registries to identify adverse events in rheumatic diseases.

Journal Article Pediatrics · November 2013 The proven effectiveness of biologics and other immunomodulatory products in inflammatory rheumatic diseases has resulted in their widespread use as well as reports of potential short- and long-term complications such as infection and malignancy. These com ... Full text Link to item Cite

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Journal Article Arthritis Res Ther · September 26, 2013 INTRODUCTION: Two replicate randomized, placebo-controlled six-month trials (RCTs) and an open-label treatment extension (OLE) comprised the pegloticase development program in patients with gout refractory to conventional therapy. In the RCTs, approximatel ... Full text Link to item Cite

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.

Journal Article Ann Rheum Dis · September 1, 2013 OBJECTIVE: To evaluate the long-term safety (up to 3 years) of treatment with pegloticase in patients with refractory chronic gout. METHODS: This open-label extension (OLE) study was conducted at 46 sites in the USA, Canada and Mexico. Patients completing ... Full text Link to item Cite

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.

Journal Article Respir Res · July 13, 2013 BACKGROUND: Acute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure. METHODS: Three investigators retrospe ... Full text Link to item Cite

Racial differences in the association of CD14 polymorphisms with serum total IgE levels and allergen skin test reactivity.

Journal Article J Asthma Allergy · 2013 BACKGROUND: The CD14 C-159T single nucleotide polymorphism (SNP) has been investigated widely as a candidate genetic locus in patients with allergic disease. There are conflicting results for the association of the CD14 C-159T SNP with total serum immunogl ... Full text Open Access Link to item Cite

Long-term safety of pegloticase in chronic gout refractory to conventional treatment

Journal Article Annals of the Rheumatic Diseases · 2013 Objective: To evaluate the long-term safety (up to 3 years) of treatment with pegloticase in patients with refractory chronic gout. Methods: This open-label extension (OLE) study was conducted at 46 sites in the USA, Canada and Mexico. Patients completing ... Full text Cite

Innovative approach to industrial lighting

Journal Article AISTech - Iron and Steel Technology Conference Proceedings · 2013 Cite

The rheumatology of gout.

Journal Article Adv Chronic Kidney Dis · November 2012 Gout is a metabolic disorder of purine metabolism with primary manifestations of acute and chronic arthritis and tophus formation. The prevalence of gout appears to be increasing and may affect up to 8 million people in the United States. The development o ... Full text Link to item Cite

Pegloticase for treating refractory chronic gout.

Journal Article Drugs Today (Barc) · July 2012 Gout is a metabolic disorder of excess uric acid accumulation that manifests clinically as inflammatory arthritis, chronic arthropathy and the formation of deposits of uric acid known as tophi. A primary objective of gout management is to reduce the excess ... Full text Link to item Cite

The clinical and environmental determinants of airway transcriptional profiles in allergic asthma.

Journal Article Am J Respir Crit Care Med · March 15, 2012 RATIONALE: Gene expression profiling of airway epithelial and inflammatory cells can be used to identify genes involved in environmental asthma. METHODS: Airway epithelia and inflammatory cells were obtained via bronchial brush and bronchoalveolar lavage ( ... Full text Link to item Cite

Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.

Journal Article Arthritis Rheum · March 2012 OBJECTIVE: To evaluate the interleukin-1 inhibitor rilonacept (Interleukin-1 Trap) for prevention of gout flares occurring in the first few months following initiation of urate-lowering therapy. METHODS: In this double-blind study, adult patients with hype ... Full text Link to item Cite

Acute Gout

Journal Article Hospital Medicine Clinics · January 1, 2012 Gout is an inflammatory arthritis resulting from the deposition of monosodium urate crystals in joints and soft tissues. This article discusses the definitions and epidemiology of acute gout. History and examination, diagnosis, management, prognosis, perfo ... Full text Cite

In reply

Journal Article JAMA · November 9, 2011 Full text Cite

Pulmonary function, bronchial reactivity, and epithelial permeability are response phenotypes to ozone and develop differentially in healthy humans.

Journal Article J Appl Physiol (1985) · September 2011 Effect of laboratory exposure to O₃ (220 ppb) and filtered air (FA) on respiratory physiology were evaluated at two time points (acute and 1 day postexposure) in healthy cohort (n = 138, 18-35 yr, 40% women) comprised mainly of Caucasian (60%) and African ... Full text Link to item Cite

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Journal Article JAMA · August 17, 2011 CONTEXT: Patients with chronic disabling gout refractory to conventional urate-lowering therapy need timely treatment to control disease manifestations related to tissue urate crystal deposition. Pegloticase, monomethoxypoly(ethylene glycol)-conjugated mam ... Full text Link to item Cite

Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy.

Journal Article J Med Econ · 2011 OBJECTIVE: Joint pain and swelling during gout flares may lead to considerable morbidity and disability, having an impact on patient work productivity and social participation. The objective of this study was to assess how gout flares affect these activiti ... Full text Link to item Cite

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Journal Article N Engl J Med · August 12, 2010 BACKGROUND: Sildenafil, a phosphodiesterase-5 inhibitor, may preferentially improve blood flow to well-ventilated regions of the lung in patients with advanced idiopathic pulmonary fibrosis, which could result in improvements in gas exchange. We tested the ... Full text Link to item Cite

Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.

Journal Article Proc Natl Acad Sci U S A · August 10, 2010 A high plasma urate concentration (PUA), related to loss of urate oxidase in evolution, is postulated to protect humans from oxidative injury. This hypothesis has broad clinical relevance, but support rests largely on in vitro data and epidemiologic associ ... Full text Link to item Cite

A natural experiment in the quality of care in gout.

Journal Article Curr Opin Rheumatol · March 2010 Full text Link to item Cite

Progress in the pharmacotherapy of gout.

Journal Article Curr Opin Rheumatol · March 2010 PURPOSE OF REVIEW: To summarize new knowledge on approved and emerging drugs used to treat hyperuricemia or the clinical manifestations of gout. RECENT FINDINGS: Results of several clinical trials provide new data on the efficacy and safety of the approved ... Full text Link to item Cite

Current Opinion in Rheumatology: Editorial introductions

Journal Article Current Opinion in Rheumatology · March 1, 2010 Full text Cite

Editors’ introduction

Journal Article Political Representation · January 1, 2010 Certainly, gentlemen, it ought to be the happiness and glory of a representative to live in the strictest union, the closest correspondence, and the most unreserved communication with his constituents. Their wishes ought to have great weight with him; thei ... Full text Cite

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.

Journal Article Ann Rheum Dis · October 2009 BACKGROUND: Recent studies suggest that blockade of the NLRP3 (cryopyrin) inflammasome interleukin 1beta (IL1beta) pathway may offer a new treatment strategy for gout. OBJECTIVE: To explore the potential utility of rilonacept (IL1 Trap) in patients with ch ... Full text Link to item Cite

Quality of life and disability in patients with treatment-failure gout.

Journal Article J Rheumatol · May 2009 OBJECTIVE: The relationship between self-reported quality of life and disability and disease severity was evaluated in subjects with treatment-failure gout (n = 110) in a prospective, 52-week, observational study. METHODS: Subjects had symptomatic crystal- ... Full text Link to item Cite

Efficacy of esomeprazole for treatment of poorly controlled asthma.

Journal Article N Engl J Med · April 9, 2009 BACKGROUND: Gastroesophageal reflux is common among patients with asthma but often causes mild or no symptoms. It is not known whether treatment of gastroesophageal reflux with proton-pump inhibitors in patients who have poorly controlled asthma without sy ... Full text Link to item Cite

Editorial introductions

Journal Article Current Opinion in Rheumatology · March 1, 2009 Cite

Gout management: let's get it right this time.

Journal Article Arthritis Rheum · November 15, 2008 Featured Publication Full text Link to item Cite

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Journal Article Arthritis Rheum · September 2008 Featured Publication OBJECTIVE: To assess the efficacy of pegloticase in achieving and maintaining plasma urate levels of <6 mg/dl in gout patients in whom other treatments have failed, and to assess the pharmacokinetics and safety of pegloticase. METHODS: Forty-one patients w ... Full text Link to item Cite

Normative values for exhaled breath condensate pH and its relationship to exhaled nitric oxide in healthy African Americans.

Journal Article J Allergy Clin Immunol · July 2008 Featured Publication BACKGROUND: Exhaled breath condensate (EBC) pH and exhaled nitric oxide (FeNO) have been proposed as markers of asthma severity. EBC pH values below 6.5 have been associated with asthma exacerbations. Protonation of airway nitrite occurs at low pH and may ... Full text Link to item Cite

Identification of a novel asthma susceptibility gene on chromosome 1qter and its functional evaluation.

Journal Article Hum Mol Genet · July 1, 2008 Asthma is a multifactorial disease, in which the intricate interplay between genetic and environmental factors underlies the overall phenotype of the disease. Using a genome-wide scan for linkage in a population comprising of Danish families, we identified ... Full text Link to item Cite

Factor analysis in the Genetics of Asthma International Network family study identifies five major quantitative asthma phenotypes.

Journal Article Clin Exp Allergy · March 2008 BACKGROUND: Asthma is a clinically heterogeneous disease caused by a complex interaction between genetic susceptibility and diverse environmental factors. In common with other complex diseases the lack of a standardized scheme to evaluate the phenotypic va ... Full text Link to item Cite

Refractory gout: what is it and what to do about it?

Journal Article Curr Opin Rheumatol · March 2008 PURPOSE OF REVIEW: The purpose of this review is to discuss the defining characteristics of refractory gout and the pharmacological management of this problem. RECENT FINDINGS: Refractory gout refers to those patients who have ongoing symptoms of active di ... Full text Link to item Cite

Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults.

Journal Article J Allergy Clin Immunol · February 2008 Featured Publication BACKGROUND: Asthma is a significant cause of morbidity and mortality for African Americans. Fraction of exhaled nitric oxide (FeNO) levels are increased in patients with asthma, and airway levels of nitric oxide metabolites regulate airway inflammation and ... Full text Link to item Cite

Smoking is associated with an age-related decline in exhaled nitric oxide.

Journal Article Eur Respir J · December 2007 Featured Publication Age-related declines in forced expiratory volume in one second are accelerated in smokers. Smoking is associated with decreased exhaled nitric oxide fraction (F(eNO)). The aim of the present study was to determine the impact of age on F(eNO) in otherwise h ... Full text Link to item Cite

Uricase and other novel agents for the management of patients with treatment-failure gout.

Journal Article Curr Rheumatol Rep · June 2007 Featured Publication Successful management of chronic gout depends on reducing body pools of urate. The benchmark of success is to maintain serum urate levels at less than 6 mg/dL using therapies such as probenecid or allopurinol. In a subset of patients with gout, these medic ... Full text Link to item Cite

Quantitative linkage genome scan for atopy in a large collection of Caucasian families.

Journal Article Hum Genet · March 2007 Featured Publication Quantitative phenotypes correlated with a complex disorder offer increased power to detect linkage in comparison to affected-unaffected classifications. Asthma is a complex disorder characterized by periods of bronchial obstruction and increased bronchial ... Full text Link to item Cite

Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.

Journal Article Arthritis Rheum · March 2007 Featured Publication OBJECTIVE: To evaluate the efficacy, immunogenicity, and tolerability of intravenous (IV) PEGylated recombinant mammalian urate oxidase (PEG-uricase) for the treatment of severe gout. METHODS: Single infusions of PEG-uricase (at doses ranging from 0.5 mg t ... Full text Link to item Cite

Update on nonsteriodal anti-inflammatory drugs.

Journal Article Curr Opin Rheumatol · May 2006 PURPOSE OF REVIEW: This review addresses recent concerns about the cardiovascular safety of nonsteroidal anti-inflammatory drugs, the disease-modifying role of these drugs in ankylosing spondylitis, and their use in the understudied pediatric population. R ... Full text Link to item Cite

A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: evidence for a major susceptibility locus on chromosome 2p.

Journal Article Eur J Hum Genet · March 2006 Featured Publication Asthma is a complex disease and the intricate interplay between genetic and environmental factors underlies the overall phenotype of the disease. Families with at least two siblings with asthma were collected from Europe, Australia and the US. A genome sca ... Full text Link to item Cite

Safety of incremental inhaled lipopolysaccharide challenge in humans.

Journal Article J Endotoxin Res · 2006 BACKGROUND: Inhalation of environmental endotoxin is important in the pathogenesis of asthma and other environmental airway diseases. Inhaled airway challenge using lipopolysaccharide in humans has been performed for over 20 years to assess the airway resp ... Full text Link to item Cite

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.

Journal Article Arthritis Res Ther · 2006 Featured Publication PEG-modified recombinant mammalian urate oxidase (PEG-uricase) is being developed as a treatment for patients with chronic gout who are intolerant of, or refractory to, available therapy for controlling hyperuricemia. In an open-label phase I trial, single ... Full text Link to item Cite

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

Journal Article Arthritis Research and Therapy · December 2, 2005 PEG-modified recombinant mammalian urate oxidase (PEG-uricase) is being developed as a treatment for patients with chronic gout who are intolerant of, or refractory to, available therapy for controlling hyperuricemia. In an open-label phase I trial, single ... Full text Cite

Emerging treatments for rheumatoid arthritis: Update

Journal Article Consultant · August 1, 2005 Early treatment with disease-modifying anti-rheumatic drugs (DMARDs)-alone or in combination-can prevent joint damage and minimize disability. Until recently, the DMARDs used predominantly in patients with rheumatoid arthritis had been methotrexate, sulfas ... Cite

Symptomatic effects of exposure to diluted air sampled from a swine confinement atmosphere on healthy human subjects.

Journal Article Environ Health Perspect · May 2005 Featured Publication Aerial emissions from a swine house at North Carolina State University's field laboratory were diluted to a level that could occur at varying distances downwind from a confined animal feeding operation (CAFO) both within and beyond the property line, and t ... Full text Link to item Cite

Bioaerosols and innate immune responses in airway diseases.

Journal Article Curr Opin Allergy Clin Immunol · October 2004 Featured Publication PURPOSE OF REVIEW: We review the role of bioaerosols in the pathogenesis of inflammatory airway disease. The focus is on recent discoveries in innate immune responses induced by common components of bioaerosols. RECENT FINDINGS: Common components of bioaer ... Full text Link to item Cite

A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma.

Journal Article Pharmacogenetics · September 2004 BACKGROUND: Cysteinyl leukotrienes (CYSLTR) are potent biological mediators in the pathophysiology of asthma for which two receptors have been characterized, CYSLTR1 and CYSLTR2. The leukotriene modifying agents currently used to control bronchoconstrictio ... Full text Link to item Cite

Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey.

Journal Article J Allergy Clin Immunol · February 2003 BACKGROUND: Previous estimates of the cost of allergic rhinitis predate the substantial increase in the use of second-generation antihistamines and intranasal corticosteroids. OBJECTIVE: We sought to update estimates of the direct costs of allergic rhiniti ... Full text Link to item Cite

Management of allergic rhinitis in the working-age population.

Journal Article Evid Rep Technol Assess (Summ) · January 2003 Featured Publication Link to item Cite

COX-2 inhibitors in rheumatoid arthritis.

Journal Article Curr Rheumatol Rep · February 2001 The selective cyclooxygenase 2 (COX-2) inhibitors have emerged as an important option in the treatment of rheumatoid arthritis (RA). Rofecoxib and celecoxib, the selective COX-2 inhibitors currently available, have shown efficacy in reducing symptoms of RA ... Full text Link to item Cite

Cytokines and adhesion molecules in the pathogenesis of vasculitis.

Journal Article Curr Rheumatol Rep · October 2000 Upregulated adhesion molecule and cytokine expression on endothelial cells and infiltrating inflammatory cells occur in most vasculitis syndromes. These observations suggest that vasculitis is associated with pathologic activation of normal immune cell cyt ... Full text Link to item Cite

Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy.

Journal Article J Immunol · February 15, 2000 The roles that thymus cytokines might play in regulating thymic atrophy are not known. Reversing thymic atrophy is important for immune reconstitution in adults. We have studied cytokine mRNA steady-state levels in 45 normal human (aged 3 days to 78 years) ... Full text Link to item Cite

Immunologic characterization of CD7-deficient mice.

Journal Article J Immunol · June 15, 1998 Human CD7 is an Ig superfamily molecule that is expressed on mature T and NK lymphocytes. Although in vitro studies have suggested a role for CD7 in lymphoid development and function, the exact function of CD7 in vivo has remained elusive. One patient has ... Link to item Cite

Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review.

Journal Article Arthritis Rheum · October 1997 OBJECTIVE: To describe the clinical, laboratory, radiologic, and histopathologic features of methotrexate (MTX)-induced lung injury in a combined cohort of selected patients with rheumatoid arthritis (RA) and all cases reported in the English-language lite ... Full text Link to item Cite

Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group.

Journal Article Ann Intern Med · September 1, 1997 BACKGROUND: Toxicity limits the use of methotrexate. OBJECTIVE: To identify risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. DESIGN: Case-control study. SETTING: One private and five academic rheumatology practices. ... Full text Link to item Cite

Rocky Mountain spotted fever presenting with acute monarticular arthritis.

Journal Article Arthritis Rheum · January 1996 This report describes a 30-year-old man who presented with an acute multisystem illness which was diagnosed as Rocky Mountain spotted fever (RMSF). Near the time of admission the patient was noted to have a newly developed aseptic monarticular arthritis of ... Full text Link to item Cite

Initial characterization of cd7 deficient mice: evidence of a role for CD7 in regulation of thymocyte development

Journal Article Journal of Investigative Medicine · January 1, 1996 Human CD7 is a 40 kilodalton member of the immunoglobulin gene superfamily that is expressed early in natural killer and T lymphocyte development. Although CD7 involvement in lymphocyte activation has been suggested by numerous studies, the functional role ... Cite

Pathogenic mechanisms of vessel damage in vasculitis syndromes.

Journal Article Rheum Dis Clin North Am · November 1995 The pathogenesis of vasculitis syndromes is via a diverse array of mechanisms that disrupt vessel integrity and produce clinical signs and symptoms of tissue ischemia. In many patients with vasculitis, it is not possible to directly classify the syndrome a ... Link to item Cite

Cell-mediated immune responses to vaccine peptides derived from the circumsporozoite protein of Plasmodium falciparum.

Journal Article J Immunol · July 15, 1989 T cell epitopes residing within vaccine candidate peptides have been identified by delayed-type hypersensitivity (DTH) responses in mice. The recombinant sporozoite vaccine candidate, R32tet32, contains at least two T epitopes, one located within the repea ... Link to item Cite